Varseta-M's registrational path in advanced CRC turns on whether Phase 1 dose-optimization data supports an FDA-aligned trial design

CytomX Therapeutics is a clinical-stage company developing Varseta-M, a targeted cancer drug for advanced colorectal cancer, which is not yet approved.

Varseta-M is a Probody-masked anti-EpCAM antibody-drug conjugate targeting advanced colorectal cancer in late-line patients with limited options. The thesis resolves on whether H2 2026 dose-optimization data are sufficient for FDA to align on a registrational monotherapy study design. The primary competitive risk is the accelerating approval of EpCAM- and TROP2-targeting ADCs—including datopotamab deruxtecan and sacituzumab govitecan—which could pre-empt available patient populations and set a high efficacy bar before Varseta-M reaches pivotal data.